DTE Obesity Direct-to-employer access model for FDA-approved obesity management medicines positions Waltz Health to engage self-insured employers with transparent pricing and integrated clinical support, presenting a sales opportunity to employers seeking cost-effective GLP-1 therapies.

Strategic Partnerships Recent partnerships with Novo Nordisk, Eli Lilly, and True Rx Health Strategists indicate strong traction with PBMs and payers; leverage these relationships to expand cross-channel distribution and accelerate employer-based drug access programs.

Cost Transparency AI-driven marketplaces aimed at reducing prescription costs and improving access align with payer and employer interests in total-cost-of-care reduction, suggesting opportunities to upsell pricing transparency and competitive bidding solutions.

EVERSANA Synergy As an EVERSANA company, Waltz Health can cross-sell commercialization services, deployment of technology-enabled pricing, distribution, and prescribing solutions to life sciences manufacturers seeking streamlined market access.

Growth & Scale Funding and revenue signals combined with a lean team (11-50 employees) underscore a growth-through-technology moat; target fast-growing employers, regional health plans, and mid-market PBMs looking to modernize drug purchasing and access.